Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd (ASPIRA) last reported results for the quarter ended Jun 2025, with sales of ₹5.25 crore and net profit of ₹0.42 crore. The stock last traded at ₹121, a market capitalisation of ₹125 crore, on a P/E of 51.9. Over the past 52 weeks the stock has ranged between ₹49 and ₹150. Figures are as of 6 Oct 2026 and are not real time.
Aspira Pathlab & Diagnostics Ltd share price and key metrics
- Current price
- ₹121
- Market cap
- ₹125 cr
- Stock P/E
- 51.9
- Book value
- ₹7.02
- ROE
- 33.0%
- ROCE
- 17.0%
- Dividend yield
- 0.00%
- 52w high / low
- 150/49.0
Metrics as of 6 Oct 2026. Not real time.
Track Aspira Pathlab & Diagnostics Ltd
Cruxal reads every Aspira Pathlab & Diagnostics Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Aspira Pathlab & Diagnostics Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 67%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 177%
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 53%
- 1 Year
- 82%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 33%
Aspira Pathlab & Diagnostics Ltd quarterly results
In the quarter ended Jun 2025, sales were ₹5.25 cr, up 13.1% from ₹4.64 cr a year earlier. Net profit was ₹0.42 cr, up 740.0% year on year.
| ₹ crore | Jun 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 2.6 | 3.82 | 4.64 | 6.18 | 5.41 | 5.78 | 5.25 |
| Expenses | 3.02 | 4.03 | 4.38 | 4.91 | 4.81 | 4.86 | 4.57 |
| Operating profit | -0.42 | -0.21 | 0.26 | 1.27 | 0.6 | 0.92 | 0.68 |
| OPM % | -16.15% | -5.50% | 5.60% | 20.55% | 11.09% | 15.92% | 12.95% |
| Other income | 0.1 | 0.08 | 0.16 | 0.08 | 0.09 | 0.13 | 0.11 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.39 | 0.38 | 0.38 | 0.36 | 0.39 | 0.37 | 0.37 |
| Profit before tax | -0.71 | -0.51 | 0.04 | 0.99 | 0.3 | 0.68 | 0.42 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -0.72 | -0.5 | 0.05 | 0.99 | 0.31 | 0.68 | 0.42 |
| EPS (₹) | -0.70 | -0.49 | 0.05 | 0.96 | 0.30 | 0.66 | 0.41 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Aspira Pathlab & Diagnostics Ltd annual results
| ₹ crore | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|
| Sales | 13.2 | 22 | 22.62 |
| Operating profit | -1.18 | 3.51 | 3.47 |
| OPM % | -8.94% | 15.95% | 15.34% |
| Net profit | -2.67 | 2.02 | 2.4 |
| EPS (₹) | -2.59 | 1.96 | 2.33 |
TTM is the trailing twelve months to the most recent quarter.
Aspira Pathlab & Diagnostics Ltd balance sheet
| ₹ crore | Mar 2024 | Mar 2025 |
|---|---|---|
| Equity capital | 10.29 | 10.29 |
| Reserves | -5.08 | -3.06 |
| Borrowings | 7.71 | 8.13 |
| Other liabilities | 1.79 | 2.11 |
| Total liabilities | 14.71 | 17.47 |
| Fixed assets | 6.79 | 6.53 |
| CWIP | 0.00 | 0.00 |
| Investments | 0.00 | 0.08 |
| Other assets | 7.92 | 10.86 |
| Total assets | 14.71 | 17.47 |
As reported by the company. Total assets equal total liabilities by construction.
Aspira Pathlab & Diagnostics Ltd cash flow
| ₹ crore | Mar 2024 | Mar 2025 |
|---|---|---|
| Cash from operations | 1.05 | 1.83 |
| Cash from investing | 0.14 | 0.12 |
| Cash from financing | -0.95 | -0.99 |
| Net cash flow | 0.24 | 0.95 |
| Free cash flow | 0.79 | 1.66 |
| CFO / operating profit | -89% | 52% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Aspira Pathlab & Diagnostics Ltd operating ratios
| Per year | Mar 2024 | Mar 2025 |
|---|---|---|
| ROCE % | — | 17.04% |
| Debtor days | 61.94 | 38.99 |
| Inventory days | 62.69 | 50.31 |
| Days payable | 101.70 | 73.00 |
| Cash conversion cycle | 22.93 | 16.30 |
| Working capital days | 25.16 | 14.10 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Aspira Pathlab & Diagnostics Ltd shareholding pattern
Promoters held 46.58% at Jun 2026, up from 18.39% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 18.55% | 18.55% | 18.39% | 18.39% | 18.39% | 18.39% | 18.39% | 46.58% |
| Public | 81.46% | 81.46% | 81.62% | 81.62% | 81.61% | 81.61% | 81.61% | 53.41% |
| No. of shareholders | 1,706 | 1,593 | 1,741 | 1,770 | 1,755 | 1,784 | 1,769 | 1,620 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd corporate filings
- Compliance Certificate under reg 74(5) of SEBI (DP) regulation, 2018 for the quarter ended September 30, 2026.Company Updatelow impact
- SEBI disclosure reveals minor share acquisition of 245 equity shares (0.00%) by Jay Arvind Bhanushali in Aspira Pathlab & Diagnostics Ltd, indicating a negligible stake increase.Insider Trading / SASTlow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd has disclosed a marginal acquisition of 245 equity…
Read the full analysis - Promoter Jay Arvind Bhanushali increases stake in Aspira Pathlab & Diagnostics Ltd via open market acquisitionInsider Trading / SASTlow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd promoter Jay Arvind Bhanushali has acquired 1,424 equity…
Read the full analysis - Aspira Pathlab & Diagnostics Limited Announces Successful Conclusion of 53rd Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Limited has successfully concluded its 53rd Annual General…
Read the full analysis - Aspira Pathlab & Diagnostics Limited Reports Significant Decline in Annual Profit for FY2026AGM/EGMlow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Limited held its 53rd Annual General Meeting on September…
Read the full analysis - Closure of Trading Window for quarter ended September 30,2026Insider Trading / SASTlow impact
- Promoter Jay Arvind Bhanushali increases stake in Aspira Pathlab & Diagnostics Ltd via open market acquisitionInsider Trading / SASTlow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd promoter, Jay Arvind Bhanushali, has acquired 1,387…
Read the full analysis - Aspira Pathlab & Diagnostics Ltd constitutes Right Issue CommitteeCompany Updatemedium impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd has formally constituted a Right Issue Committee to…
Read the full analysis - Aspira Pathlab & Diagnostics Ltd announces board meeting to consider fundraisingCompany Updatemedium impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd has issued an intimation under Regulation 30 regarding a…
Read the full analysis - Aspira Pathlab & Diagnostics Limited Announces Plans for Rights Issue of up to 65 croreBoard Meetinghigh impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Limited has announced a board-approved plan to raise funds…
Read the full analysis - Promoter Jay Arvind Bhanushali increases stake in Aspira Pathlab & Diagnostics Ltd via open market purchaseInsider Trading / SASTlow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd promoter Jay Arvind Bhanushali has acquired 74 equity…
Read the full analysis - Aspira Pathlab & Diagnostics Limited announces board meeting to consider capital raising proposalBoard Meetinghigh impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Limited has scheduled a board meeting for September 12…
Read the full analysis - Promoter Jay Arvind Bhanushali increases stake in Aspira Pathlab & Diagnostics Ltd via open market purchaseInsider Trading / SASTlow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd promoter Jay Arvind Bhanushali has acquired 623 equity…
Read the full analysis - Promoter Jay Arvind Bhanushali increases stake in Aspira Pathlab & Diagnostics Ltd via open market purchaseInsider Trading / SASTlow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd promoter Jay Arvind Bhanushali has acquired 957 equity…
Read the full analysis - Aspira Pathlab & Diagnostics Ltd dispatches Annual Report for FY 2025-26 to non-email shareholdersCompany Updatelow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd has fulfilled its regulatory obligation under SEBI…
Read the full analysis - Aspira Pathlab & Diagnostics Limited Announces 53rd Annual General Meeting for September 25, 2026Company Updatelow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Limited has issued a formal notice for its 53rd Annual…
Read the full analysis - Aspira Pathlab & Diagnostics Ltd announces 31st AGM and FY 2025-26 Annual ReportOtherslow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd has issued the notice for its 31st Annual General…
Read the full analysis - Aspira Pathlab & Diagnostics Limited Announces 53rd AGM, Management Changes, and Material Related Party TransactionsAGM/EGMhigh impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Limited has scheduled its 53rd Annual General Meeting for…
Read the full analysis - Aspira Pathlab & Diagnostics Ltd announces 53rd Annual General Meeting and book closure datesCorp. Actionlow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd has issued an intimation regarding its 53rd Annual…
Read the full analysis - Aspira Pathlab & Diagnostics Ltd announces 53rd Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Ltd has issued a newspaper advertisement regarding the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.